Wilson's disease

Parkinsonism and Related Disorders

Volumn 15, Issue SUPPL. 3, 2009, Pages

  Gouider Khouja, Neziha ^a  

^a Institut National de Neurologie Tunisia   (Tunisia)

Author keywords

Inborn errors of metabolism; Review; Wilson's disease

Indexed keywords

COPPER; PENICILLAMINE; TETRATHIOMOLYBDATE AMMONIUM; TRIENTINE; WILSON DISEASE PROTEIN; ZINC;

ARTICLE; BONE MARROW SUPPRESSION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; EYE DISEASE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; INTESTINE ABSORPTION; LIVER DISEASE; LIVER FAILURE; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; MENTAL DISEASE; MOLECULAR BIOLOGY; NEPHROTOXICITY; NEUROLOGIC DISEASE; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; SIDE EFFECT; SKIN DISEASE; TREATMENT INDICATION; WILSON DISEASE;

HEPATOLENTICULAR DEGENERATION; HUMANS;

EID: 71849090577     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(09)70798-9     Document Type: Article

References (41)

1. Wilson S. Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver. Brain 34 (1912) 295-509
2. Saudubray J.M., Sedel F., and Walter J.H. Clinical approach to treatable inborn metabolic diseases: an introduction. Metab Dis 29 (2006) 261-274
3. Sedel F., Saudubray J.M., Roze E., Agid Y., and Vidailhet M. Movement disorders and inborn errors of metabolism in adults: A diagnostic approach. J Inherit Metab Disord 31 (2008) 308-313
4. Ala A., Walker A.P., Ashkan K., Dooley J.S., and Schilsky M.L. Wilson's disease. J Neurol Neurosurg Psychiatry 67 (1999) 195-198
5. Ala A., Borjigin J., Rochwarger A., and Schilsky M. Wilson disease in septuagenarian siblings: raising the bar for diagnosis. Hepatology 41 (2005) 668-670
6. Frydman M., Bonne-Tamir B., Farrer L.A., et al. Assignment of the gene for Wilson disease to chromosome 13: linkage to the esterase D locus. Proc Natl Acad Sci USA 82 (1985) 1819-1821
7. Bull P.C., Thomas G.R., Rommens J.M., Forbes J.R., and Cox D.W. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet 5 (1993) 327-337
8. Tanzi R.E., Petrukhin K., Chernov I., et al. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet 5 (1993) 344-350
9. Yamaguchi Y., Heiny M.E., and Gitlin J.D. Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease. Biochem Biophys Res Commun 197 (1993) 271-277
10. Safaei R., and Howell S.B. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol 3 (2005) 13-23
11. van Dongen E.M., Klomp L.W., and Merkx M. Copper-dependent protein-protein interactions studied by yeast two-hybrid analysis. Biochem Biophys Res Commun 323 (2004) 789-795
12. Roelofsen H., Wolters H., Van Luyn M.J., Miura N., Kuipers F., and Vonk R.J. Copper-induced apical trafficking of ATP7B in polarized hepatoma cells provides a mechanism for biliary copper excretion. Gastroenterology 119 (2000) 782-793
13. Alt E., Sternlieb I., and Goldfischer S. The cytopathology of metal overload. Int Rev Exp Pathol 31 (1990) 165-188
14. Sternlieb I. Mitochondrial and fatty changes in hepatocytes of patients with Wilson's disease. Gastroenterology 55 (1968) 354-367
15. Schilsky M.L., Scheinberg I.H., and Sternlieb I. Prognosis of Wilsonian chronic active hepatitis. Gastroenterology 100 (1991) 762-767
16. Muller T., Langner C., Fuchsbichler A., et al. Immunohistochemical analysis of Mallory bodies in Wilsonian and non-Wilsonian hepatic copper toxicosis. Hepatology 39 (2004) 963-969
17. Strand S., Hofmann W.J., Grambihler A., et al. Hepatic failure and liver cell damage in acute Wilson's disease involve CD95 (APO-1/Fas) mediated apoptosis. Nat Med 4 (1998) 588-593
18. Opalski A. Type special de cellules neurologiques dans la degenerescence lenticulaire progressive. Z Ges Neurol Psychiatrie 124 (1930) 420
19. Pietrangelo A. Inherited metabolic diseases of the liver. Curr Opin Gastroenterol 25 (2009) 209-214
20. Medici V., Mirante V.G., Fassati L.R., et al. Monotematica AISF 2000 OLT Study Group. Liver transplantation for Wilson's disease: The burden of neurological and psychiatric disorders. Liver Transpl 11 (2005) 1056-1063
21. Santos R.G., Alissa F., Reyes J., Teot L., and Ameen N. Fulminant hepatic failure: Wilson's disease or autoimmune hepatitis? Implications for transplantation. Pediatr Transplant 9 (2005) 112-116
22. King A.D., Walshe J.M., Kendall B.E., et al. Cranial MR imaging in Wilson's disease. AJR Am J Roentgenol 167 (1996) 1579-1584
23. Sinha S., Taly A.B., Ravishankar S., et al. Wilson's disease: cranial MRI observations and clinical correlation. Neuroradiology 48 (2006) 613-621
24. Kozic D., Svetel M., Petrovic B., Dragasevic N., Semnic R., and Kostic V.S. MR imaging of the brain in patients with hepatic form of Wilson's disease. Eur J Neurol 10 (2003) 587-592
25. Richard J.M., and Friendly D.S. Ocular findings in pediatric systemic disease. Pediatr Clin North Am 30 (1983) 1123-1144
26. Williams H.P., and Walshe J.M. "Sunflower cataract" in Wilson's disease. BMJ 3 (1969) 95-96
27. Wiebers D.O., Hollenhorst R.W., and Goldstein N.P. The ophthalmologic manifestations of Wilson's disease. Mayo Clin Proc 52 (1977) 409-416
28. Mark C.M., and Lam C.W. Diagnosis of Wilson's disease. Crit Rev Clin Lab Sci 45 (2008) 263-290
29. Ferenci P., Caca K., Loudianos G., et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int 23 (2003) 139-142
30. Roberts E.A., and Schilsky M.L. A practice guideline on Wilson disease. Hepatology 37 (2003) 1475-1492
31. Gibbs K.R., and Walshe J.M. Penicillamine and pyridoxine requirements in man. Lancet 309 (1966) 175-179
32. Brewer G.J., Terry C.A., Aisen A.M., and Hill G.M. Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. Arch Neurol 44 (1987) 490-493
33. Schilsky M.N. Treatment of Wilson's disease: what are the relative roles of penicillamine, trientine, and zinc supplementation?. Curr Gastroenterol Rep 3 (2001) 54-59
34. Ferenci P. Review article: diagnosis and current therapy of Wilson's disease. Aliment Pharmacol Ther 19 (2004) 157-165
35. Brewer G.J. Neurologically presenting Wilson's disease: epidemiology, pathophysiology and treatment. CNS Drugs 19 (2005) 185-192
36. Brewer G.J., Askari F., Lorincz M.T., et al. Treatment of Wilson disease with ammonium tetrathiomolybdate. IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol (2006)
37. Brewer G.J. The use of copper lowering therapy with tetrathiomolybdate in medicine. Expert Opin Invest Drugs 18 (2009) 89-97
38. Askari F.K., Greenson, Dick R.D., Johnson V.D., and Brewer G.J. Treatment of Wilson's disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc. J Lab Clin Med 142 (2003) 385-390
39. Brewer G.J., Hedera P., Kluin K.J., et al. Treatment of Wilson's disease with ammonium tetrathiomolybdate. III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 60 (2003) 379-385
40. Schilsky M.L., Scheinberg I.H., and Sternlieb I. Liver transplantation for Wilson's disease: indications and outcome. Hepatology 19 (1994) 583-587
41. Brewer G.J., Dick R.D., Johnson V., et al. Treatment of Wilson's disease with zinc: XV. Long-term follow-up studies. J Lab Clin Med 132 (1998) 264-278